Cancer is one of the most prevalent and deadliest diseases globally, and the incidence and the number of survivors continue to increase in most developed countries. Cancer patient relapse and metastatic progression remain today great challenges despite advances in anticancer drugs in the past decades. There is therefore a renewed interest in chemoprevention that may be described as the use of natural, synthetic, or biological agents to prevent, reverse or delay the occurrence of malignancy.
We welcome articles on the development of new pharmacologically active compounds to be used as chemoprevention agents or recent insights on existing drugs able to prevent initial phases of carcinogenesis or reverse the progression of premalignant lesions into invasive tumors.
We welcome your review and original articles that shed light on the challenges and opportunities related to chemoprevention drugs. This includes new positioning of existing drugs (incl. optimization and reduction in side effects) and mechanistic dissection of tumor-suppressing strategies (radical scavengers, drug metabolizing enzyme modulators, DNA repair inducers, blockers of carcinogen uptake, apoptosis, and senescence inducers, etc.). The collection of manuscripts will be published as a special issue of the journal.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Cancer is one of the most prevalent and deadliest diseases globally, and the incidence and the number of survivors continue to increase in most developed countries. Cancer patient relapse and metastatic progression remain today great challenges despite advances in anticancer drugs in the past decades. There is therefore a renewed interest in chemoprevention that may be described as the use of natural, synthetic, or biological agents to prevent, reverse or delay the occurrence of malignancy.
We welcome articles on the development of new pharmacologically active compounds to be used as chemoprevention agents or recent insights on existing drugs able to prevent initial phases of carcinogenesis or reverse the progression of premalignant lesions into invasive tumors.
We welcome your review and original articles that shed light on the challenges and opportunities related to chemoprevention drugs. This includes new positioning of existing drugs (incl. optimization and reduction in side effects) and mechanistic dissection of tumor-suppressing strategies (radical scavengers, drug metabolizing enzyme modulators, DNA repair inducers, blockers of carcinogen uptake, apoptosis, and senescence inducers, etc.). The collection of manuscripts will be published as a special issue of the journal.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.